Autologous Cell Therapy Market Size - Global Industry, Share, Analysis, Trends and Forecast 2023 - 2032
CHAPTER 1. Industry Overview of Autologous Cell Therapy Market
1.1. Definition and Scope
1.1.1. Definition of Autologous Cell Therapy
1.1.2. Market Segmentation
1.1.3. Years Considered for the Study
1.1.4. Assumptions and Acronyms Used
1.1.4.1. Market Assumptions and Market Forecast
1.1.4.2. Acronyms Used in Global Autologous Cell Therapy Market
1.2. Summary
1.2.1. Executive Summary
1.2.2. Autologous Cell Therapy Market BySource
1.2.3. Autologous Cell Therapy Market By Application
1.2.4. Autologous Cell Therapy Market By End-use
1.2.5. Autologous Cell Therapy MarketBy Region
CHAPTER 2. Research Approach
2.1. Methodology
2.1.1. Research Programs
2.1.2. Market Size Estimation
2.1.3. Market Breakdown and Data Triangulation
2.2. Data Source
2.2.1. Secondary Source
2.2.2. Primary Source
CHAPTER 3. Market Dynamics And Competition Analysis
3.1. Market Drivers
3.1.1. Driver 1
3.1.2. Driver 2
3.2. Restraints and Challenges
3.2.1. Restraint 1
3.2.2. Restraint 2
3.3. Growth Opportunities
3.3.1. Opportunity 1
3.3.2. Opportunity 2
3.4. Porter’s Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of Substitute
3.4.4. Threat of New Entrants
3.4.5. Degree of Competition
3.5. Market Concentration Ratio and Market Maturity Analysis of Autologous Cell Therapy Market
3.5.1. Go To Market Strategy
3.5.1.1. Introduction
3.5.1.2. Growth
3.5.1.3. Maturity
3.5.1.4. Saturation
3.5.1.5. Possible Development
3.6. Technological Roadmap for Autologous Cell Therapy Market
3.7. Value Chain Analysis
3.7.1. List of Key Manufacturers
3.7.2. List of Customers
3.7.3. Level of Integration
3.8. Price Trend of Key Raw Material
3.8.1. Raw material suppliers
3.8.2. Proportion of Manufacturing Cost Structure
3.8.2.1. Raw Material
3.8.2.2. Labor Cost
3.8.2.3. Manufacturing Expense
3.9. Regulatory Compliance
3.10. Competitive Landscape, 2022
3.10.1. Player Positioning Analysis
3.10.2. Key Strategies Adopted By Leading Players
CHAPTER 4. Manufacturing Plant Analysis
4.1. Manufacturing Plant Location and Establish Date of Major Manufacturers in 2022
4.2. R&D Status of Major Manufacturers in 2022
CHAPTER 5. Autologous Cell Therapy Market BySource
5.1. Introduction
5.2. Autologous Cell Therapy Revenue BySource
5.2.1. Autologous Cell Therapy Revenue (USD Billion) and Forecast, By Source, 2020-2032
5.2.2. Bone Marrow
5.2.2.1. Bone Marrow Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
5.2.3. Mesenchymal Stem Cells
5.2.3.1. Mesenchymal Stem Cells Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
5.2.4. Epidermis
5.2.4.1. Epidermis Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
5.2.5. Chondrocytes
5.2.5.1. Chondrocytes Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
5.2.6. Haematopoietic Stem Cells
5.2.6.1. Haematopoietic Stem Cells Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
5.2.7. Others
5.2.7.1. Others Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
CHAPTER 6. Autologous Cell Therapy Market By Application
6.1. Introduction
6.2. Autologous Cell Therapy Revenue By Application
6.2.1. Autologous Cell Therapy Revenue (USD Billion) and Forecast, By Application, 2020-2032
6.2.2. Cancer
6.2.2.1. Cancer Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.3. Cardiovascular Disorders
6.2.3.1. Cardiovascular Disorders Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.4. Neurodegenerative Disorders
6.2.4.1. Neurodegenerative Disorders Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.5. Autoimmune Disorders
6.2.5.1. Autoimmune Disorders Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.6. Wound Healing
6.2.6.1. Wound Healing Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.7. Orthopedics
6.2.7.1. Orthopedics Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.8. Others
6.2.8.1. Others Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
CHAPTER 7. Autologous Cell Therapy Market By End-use
7.1. Introduction
7.2. Autologous Cell Therapy Revenue By End-use
7.2.1. Autologous Cell Therapy Revenue (USD Billion) and Forecast, By End-use, 2020-2032
7.2.2. Hospitals & Clinics
7.2.2.1. Hospitals & Clinics Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
7.2.3. Academics & Research
7.2.3.1. Academics & Research Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
7.2.4. Ambulatory Centers
7.2.4.1. Ambulatory Centers Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
7.2.5. Others
7.2.5.1. OthersMarket Revenue (USD Billion) and Growth Rate (%), 2020-2032
CHAPTER 8. North AmericaAutologous Cell Therapy Market By Country
8.1. North America Autologous Cell Therapy Market Overview
8.2. U.S.
8.2.1. U.S. Autologous Cell Therapy Revenue (USD Billion) and Forecast BySource, 2020-2032
8.2.2. U.S. Autologous Cell Therapy Revenue (USD Billion) and Forecast By Application, 2020-2032
8.2.3. U.S. Autologous Cell Therapy Revenue (USD Billion) and Forecast By End-use, 2020-2032
8.3. Canada
8.3.1. Canada Autologous Cell Therapy Revenue (USD Billion) and Forecast BySource, 2020-2032
8.3.2. Canada Autologous Cell Therapy Revenue (USD Billion) and Forecast By Application, 2020-2032
8.3.3. Canada Autologous Cell Therapy Revenue (USD Billion) and Forecast By End-use, 2020-2032
8.4. North America PEST Analysis
CHAPTER 9. Europe Autologous Cell Therapy Market By Country
9.1. Europe Autologous Cell Therapy market Overview
9.2. U.K.
9.2.1. U.K. Autologous Cell Therapy Revenue (USD Billion) and Forecast BySource, 2020-2032
9.2.2. U.K. Autologous Cell Therapy Revenue (USD Billion) and Forecast By Application, 2020-2032
9.2.3. U.K. Autologous Cell Therapy Revenue (USD Billion) and Forecast By End-use, 2020-2032
9.3. Germany
9.3.1. Germany Autologous Cell Therapy Revenue (USD Billion) and Forecast BySource, 2020-2032
9.3.2. Germany Autologous Cell Therapy Revenue (USD Billion) and Forecast By Application, 2020-2032
9.3.3. Germany Autologous Cell Therapy Revenue (USD Billion) and Forecast By End-use, 2020-2032
9.4. France
9.4.1. France Autologous Cell Therapy Revenue (USD Billion) and Forecast BySource, 2020-2032
9.4.2. France Autologous Cell Therapy Revenue (USD Billion) and Forecast By Application, 2020-2032
9.4.3. France Autologous Cell Therapy Revenue (USD Billion) and Forecast By End-use, 2020-2032
9.5. Spain
9.5.1. Spain Autologous Cell Therapy Revenue (USD Billion) and Forecast BySource, 2020-2032
9.5.2. Spain Autologous Cell Therapy Revenue (USD Billion) and Forecast By Application, 2020-2032
9.5.3. Spain Autologous Cell Therapy Revenue (USD Billion) and Forecast By End-use, 2020-2032
9.6. Rest of Europe
9.6.1. Rest of Europe Autologous Cell Therapy Revenue (USD Billion) and Forecast BySource, 2020-2032
9.6.2. Rest of Europe Autologous Cell Therapy Revenue (USD Billion) and Forecast By Application, 2020-2032
9.6.3. Rest of Europe Autologous Cell Therapy Revenue (USD Billion) and Forecast By End-use, 2020-2032
9.7. Europe PEST Analysis
CHAPTER 10. Asia Pacific Autologous Cell Therapy Market By Country
10.1. Asia Pacific Autologous Cell Therapy market Overview
10.2. China
10.2.1. China Autologous Cell Therapy Revenue (USD Billion) and Forecast BySource, 2020-2032
10.2.2. China Autologous Cell Therapy Revenue (USD Billion) and Forecast By Application, 2020-2032
10.2.3. China Autologous Cell Therapy Revenue (USD Billion) and Forecast By End-use, 2020-2032
10.3. Japan
10.3.1. Japan Autologous Cell Therapy Revenue (USD Billion) and Forecast BySource, 2020-2032
10.3.2. Japan Autologous Cell Therapy Revenue (USD Billion) and Forecast By Application, 2020-2032
10.3.3. Japan Autologous Cell Therapy Revenue (USD Billion) and Forecast By End-use, 2020-2032
10.4. India
10.4.1. India Autologous Cell Therapy Revenue (USD Billion) and Forecast BySource, 2020-2032
10.4.2. India Autologous Cell Therapy Revenue (USD Billion) and Forecast By Application, 2020-2032
10.4.3. India Autologous Cell Therapy Revenue (USD Billion) and Forecast By End-use, 2020-2032
10.5. Australia
10.5.1. Australia Autologous Cell Therapy Revenue (USD Billion) and Forecast BySource, 2020-2032
10.5.2. Australia Autologous Cell Therapy Revenue (USD Billion) and Forecast By Application, 2020-2032
10.5.3. Australia Autologous Cell Therapy Revenue (USD Billion) and Forecast By End-use, 2020-2032
10.6. South Korea
10.6.1. South Korea Autologous Cell Therapy Revenue (USD Billion) and Forecast BySource, 2020-2032
10.6.2. South Korea Autologous Cell Therapy Revenue (USD Billion) and Forecast By Application, 2020-2032
10.6.3. South Korea Autologous Cell Therapy Revenue (USD Billion) and Forecast By End-use, 2020-2032
10.7. Rest of Asia-Pacific
10.7.1. Rest of Asia-Pacific Autologous Cell Therapy Revenue (USD Billion) and Forecast BySource, 2020-2032
10.7.2. Rest of Asia-Pacific Autologous Cell Therapy Revenue (USD Billion) and Forecast By Application, 2020-2032
10.7.3. Rest of Asia-Pacific Autologous Cell Therapy Revenue (USD Billion) and Forecast By End-use, 2020-2032
10.8. Asia Pacific PEST Analysis
CHAPTER 11. Latin America Autologous Cell Therapy Market By Country
11.1. Latin AmericaAutologous Cell Therapy market Overview
11.2. Brazil
11.2.1. Brazil Autologous Cell Therapy Revenue (USD Billion) and Forecast BySource, 2020-2032
11.2.2. Brazil Autologous Cell Therapy Revenue (USD Billion) and Forecast By Application, 2020-2032
11.2.3. Brazil Autologous Cell Therapy Revenue (USD Billion) and Forecast By End-use, 2020-2032
11.3. Mexico
11.3.1. Mexico Autologous Cell Therapy Revenue (USD Billion) and Forecast BySource, 2020-2032
11.3.2. Mexico Autologous Cell Therapy Revenue (USD Billion) and Forecast By Application, 2020-2032
11.3.3. Mexico Autologous Cell Therapy Revenue (USD Billion) and Forecast By End-use, 2020-2032
11.4. Rest of Latin America
11.4.1. Rest of Latin America Autologous Cell Therapy Revenue (USD Billion) and Forecast BySource, 2020-2032
11.4.2. Rest of Latin America Autologous Cell Therapy Revenue (USD Billion) and Forecast By Application, 2020-2032
11.4.3. Rest of Latin America Autologous Cell Therapy Revenue (USD Billion) and Forecast By End-use, 2020-2032
11.5. Latin America PEST Analysis
CHAPTER 12. Middle East & Africa Autologous Cell Therapy Market By Country
12.1. Middle East & Africa Autologous Cell Therapy market Overview
12.2. GCC
12.2.1. GCC Autologous Cell Therapy Revenue (USD Billion) and Forecast BySource, 2020-2032
12.2.2. GCC Autologous Cell Therapy Revenue (USD Billion) and Forecast By Application, 2020-2032
12.2.3. GCC Autologous Cell Therapy Revenue (USD Billion) and Forecast By End-use, 2020-2032
12.3. South Africa
12.3.1. South Africa Autologous Cell Therapy Revenue (USD Billion) and Forecast BySource, 2020-2032
12.3.2. South Africa Autologous Cell Therapy Revenue (USD Billion) and Forecast By Application, 2020-2032
12.3.3. South Africa Autologous Cell Therapy Revenue (USD Billion) and Forecast By End-use, 2020-2032
12.4. Rest of Middle East & Africa
12.4.1. Rest of Middle East & Africa Autologous Cell Therapy Revenue (USD Billion) and Forecast BySource, 2020-2032
12.4.2. Rest of Middle East & Africa Autologous Cell Therapy Revenue (USD Billion) and Forecast By Application, 2020-2032
12.4.3. Rest of Middle East & Africa Autologous Cell Therapy Revenue (USD Billion) and Forecast By End-use, 2020-2032
12.5. Middle East & Africa PEST Analysis
CHAPTER 13. Player Analysis Of Autologous Cell Therapy Market
13.1. Autologous Cell Therapy Market Company Share Analysis
13.2. Competition Matrix
13.2.1. Competitive Benchmarking Of Key Players By Price, Presence, Market Share, And R&D Investment
13.2.2. New ProductLaunches and Product Enhancements
13.2.3. Mergers And Acquisition InGlobal Autologous Cell Therapy Market
13.2.4. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements
CHAPTER 14. Company Profile
14.1. Vericel Corporation
14.1.1. Company Snapshot
14.1.2. Business Overview
14.1.3. Financial Overview
14.1.3.1. Revenue (USD Billion), 2022
14.1.3.2. Vericel Corporation2022Autologous Cell TherapyBusiness Regional Distribution
14.1.4. Product /Service and Specification
14.1.5. Recent Developments & Business Strategy
14.2. Kite Pharma
14.3. Novartis AG
14.4. Spark Therapeutics
14.5. Organogenesis Inc.
14.6. bluebird bio
14.7. Osiris Therapeutics, Inc.
14.8. Fibrocell Science, Inc.
14.9. JCR Pharmaceuticals Co., Ltd.
14.10. KolonTissueGene, Inc.
14.11. MEDIPOST Co., Ltd.
14.12. TiGenix NV
Frequently Asked Questions
What was the market size of the global autologous cell therapy in 2022?
The market size of autologous cell therapy was USD 6.1 Billion in 2022.
What is the CAGR of the global autologous cell therapy market from 2023 to 2032?
The CAGR of autologous cell therapy is 19.1% during the analysis period of 2023 to 2032.
Which are the key players in the autologous cell therapy market?
The key players operating in the global market are including Vericel Corporation, Kite Pharma, Novartis AG, Spark Therapeutics, Organogenesis Inc., bluebird bio, Osiris Therapeutics, Inc., Fibrocell Science, Inc., JCR Pharmaceuticals Co., Ltd., KolonTissueGene, Inc., MEDIPOST Co., Ltd., and TiGenix NV.
Which region dominated the global autologous cell therapy market share?
North America held the dominating position in autologous cell therapy industry during the analysis period of 2023 to 2032.
Which region registered fastest CAGR from 2023 to 2032?
Asia-Pacific region exhibited fastest growing CAGR for market of autologous cell therapy during the analysis period of 2023 to 2032.
What are the current trends and dynamics in the global autologous cell therapy industry?
The current trends and dynamics in the autologous cell therapy industry include increasing prevalence of chronic diseases, growing demand for personalized medicine, and advancements in technology for cell culture and genetic engineering.
Which application held the maximum share in 2022?
The cancer application held the maximum share of the autologous cell therapy industry.
Select Licence Type
Connect with our sales team
Why Acumen Research And Consulting
100%
Customer Satisfaction
24x7
Availability - we are always there when you need us
200+
Fortune 50 Companies trust Acumen Research and Consulting
80%
of our reports are exclusive and first in the industry
100%
more data and analysis
1000+
reports published till date
